Go to the page content
Obesity

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

Locations

United States

Start date

18/12/2024

Identifiers

Trial ID NN9662-7694,
NCT number NCT06737536,
Eudract number Not Available

Summary

This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.

Trial Overview:

Condition

Overweight

Obesity

Treatment

DRUG: NNC0662-0419

OTHER: Placebo (NNC0662-0419)

Study type

INTERVENTIONAL

Trial duration

Dec 18 2024 - Jul 17 2025

Participants

100

Phase

I

Are you eligible?

Gender

Male and female

Age

19 to 55 years old

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.